fda warning compounding semaglutide october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Drug Recalls and Warnings:

10.4103/2045-080X.183029 Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D: Glutathione for skin lightening: a regnant myth or evidence-based verity

The ghk-cu topical use provides several benefits including direct supply to skin tissue, non-invasive use, excellent for facial anti-aging, and suitable for those who prefer not to inject

Elantary R, Othman S (2024) Role of L-carnitine in cardiovascular health: literature review

Biochem Cell Biol 90(3):320328 Baker HM et al (2000) Metal substitution in transferrins: specific binding of cerium(IV) revealed by the crystal structure of cerium-substituted human lactoferrin